Takeda Faces Antitrust Trial Over Alleged Generic Actos Delays in July

A legal battle concerning Takeda Pharmaceuticals Co. and its diabetes medication Actos is set to reach a decisive phase this July. In recent proceedings, a New York federal court declined Takeda’s attempt to dismiss claims that it unlawfully delayed the introduction of generic versions of Actos. The trial is poised to address these allegations, highlighting critical issues of competition and antitrust law in the pharmaceutical sector. For more detailed information, visit the original article by Law360.